Anti-Obinutuzumab ELISA Kit

Catalog No.

KAC90702

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Obinutuzumab has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and Anti-Obinutuzumab will be captured by immobilized Obinutuzumab. After washing away any unbound substances, a biotin-labeled Obinutuzumab is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Obinutuzumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Anti-Obinutuzumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

6.25 - 400 ng/mL

Sensitivity

2.29 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	194.0	46.4	11.3	191.2	47.0	9.8
Standard deviation	8.1	2.2	1.1	7.7	4.1	1.2
CV (%)	4.2	4.7	10.0	4.0	8.7	12.0

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

GA101,RG7159,RO5072759,Afutuzumab,CAS: 949142-50-1

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance., PMID:40501414

Advances and challenges in leukemia treatment: A focus on monoclonal antibodies and emerging therapies., PMID:40486885

In active lupus nephritis, adding obinutuzumab to standard therapy increased complete renal response rates at 76 wk., PMID:40456159

Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study., PMID:40453137

Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?, PMID:40427101

Obinutuzumab in Patients With Active Lupus Nephritis: A Meta-Analysis., PMID:40424616

Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460

Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia., PMID:40413154

Successful treatment of pemphigus vulgaris with obinutuzumab., PMID:40406957

Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy., PMID:40388905

Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report., PMID:40356910

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403., PMID:40355425

Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia - real-world data from a hemato-oncology center., PMID:40353625

Obinutuzumab as a Promising Treatment for Membranous Nephropathy., PMID:40352879

CRISPRi screening identifies PIKfyve as a co-therapeutic target for obinutuzumab., PMID:40342289

Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy., PMID:40336511

[Seronegativity and anti-CD20: When a treatment compromises the diagnosis]., PMID:40312237

Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports., PMID:40303416

Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients., PMID:40303206

Immunotherapy for autoimmune encephalitis., PMID:40301313

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group., PMID:40285420

Osteonecrosis of the Jaw Associated with Obinutuzumab in a Patient with Preceding Follicular Non-Hodgkin's Lymphoma., PMID:40278317

How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance., PMID:40270461

Successful Treatment of Ocular Post-Transplant Lymphoproliferative Disorder with Obinutuzumab in an 8-Year-Old Boy Following Kidney Transplant: A Case Report., PMID:40255019

An autopsy for persistent coronavirus disease 2019 pneumonia during follicular lymphoma treatment: A case report., PMID:40254437

Clinical characteristics, treatment patterns and outcomes of patients with follicular lymphoma in Colombia: a real-world evidence cohort study., PMID:40227475

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies., PMID:40225374

Obinutuzumab-induced Acute Thrombocytopenia Mimicking Immune Thrombocytopenia in a Patient with Follicular Lymphoma., PMID:40222942

Obinutuzumab in focal segmental glomerulonephritis resistant to treatment., PMID:40221341

AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia., PMID:40220751

B cell depletion in lupus nephritis: From disappointments to hopes, despite some concerns., PMID:40220749

A New Pulmonary Nodule in a Patient With a History of Lymphoma., PMID:40210319

Obinutuzumab: a new frontier in the treatment of refractory idiopathic membranous nephropathy., PMID:40205126

Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN., PMID:40198878

Obinutuzumab in patients with repeated lupus nephritis flares: A case series., PMID:40186329

Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study., PMID:40181090

A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia., PMID:40170466

Treatment of nephrotic syndrome with anti-CD20 therapies in pregnancy: a case series and review of the literature., PMID:40148078

Preclinical B cell depletion and safety profile of a brain-shuttled crystallizable fragment-silenced CD20 antibody., PMID:40118783

Zanubrutinib, venetoclax, and obinutuzumab in R/R CLL., PMID:40111334

The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease., PMID:40104551

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia., PMID:40101233

Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease., PMID:40101168

Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region., PMID:40078401

Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI., PMID:40075647

Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study., PMID:40074837

Bilateral drusenoid deposits with subretinal fluid and cystoid macular edema in a serum anti-phospholipase A2 receptor antibody positive patient: A case report., PMID:40061915

[The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP]., PMID:40059685

Obinutuzumab effective for lupus nephritis., PMID:40055568

Document Download

Anti-Obinutuzumab ELISA Kit.pdf